Gloria A Aguayo1, Adam Hulman2,3,4, Michel T Vaillant5, Anne-Françoise Donneau6, Anna Schritz5, Saverio Stranges7,8, Laurent Malisoux7, Laetitia Huiart7, Michèle Guillaume6, Séverine Sabia9,10, Daniel R Witte2,3. 1. Population Health Department, Luxembourg Institute of Health, Strassen, Luxembourg gloria.aguayo@lih.lu. 2. Department of Public Health, Aarhus University, Aarhus, Denmark. 3. Danish Diabetes Academy, Odense, Denmark. 4. Steno Diabetes Center Aarhus, Aarhus, Denmark. 5. Competence Center for Methodology and Statistics, Luxembourg Institute of Health, Strassen, Luxembourg. 6. Department of Public Health Sciences, University of Liège, Liège, Belgium. 7. Population Health Department, Luxembourg Institute of Health, Strassen, Luxembourg. 8. Department of Epidemiology and Biostatistics and Department of Family Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. 9. INSERM U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Paris, France. 10. Department of Epidemiology and Public Health, University College London, London, U.K.
Abstract
OBJECTIVE: Frailty is a dynamic state of vulnerability in the elderly. We examined whether individuals with overt diabetes or higher levels of HbA1c or fasting plasma glucose (FG) experience different frailty trajectories with aging. RESEARCH DESIGN AND METHODS: Diabetes, HbA1c, and FG were assessed at baseline, and frailty status was evaluated with a 36-item frailty index every 2 years during a 10-year follow-up among participants from the English Longitudinal Study of Ageing (ELSA). Mixed-effects models with age as time scale were used to assess whether age trajectories of frailty differed as a function of diabetes, HbA1c, and FG. RESULTS: Among 5,377 participants (median age [interquartile range] 70 [65, 77] years, 45% men), 35% were frail at baseline. In a model adjusted for sex, participants with baseline diabetes had an increased frailty index over aging compared with those without diabetes. Similar findings were observed with higher levels of HbA1c, while FG was not associated with frailty. In a model additionally adjusted for income, social class, smoking, alcohol, and hemoglobin, only diabetes was associated with an increased frailty index. Among nonfrail participants at baseline, both diabetes and HbA1c level were associated with a higher increased frailty index over time. CONCLUSIONS: People with diabetes or higher HbA1c levels at baseline had a higher frailty level throughout later life. Nonfrail participants with diabetes or higher HbA1c also experienced more rapid deterioration of frailty level with aging. This observation could reflect a role of diabetes complications in frailty trajectories or earlier shared determinants that contribute to diabetes and frailty risk in later life.
OBJECTIVE: Frailty is a dynamic state of vulnerability in the elderly. We examined whether individuals with overt diabetes or higher levels of HbA1c or fasting plasma glucose (FG) experience different frailty trajectories with aging. RESEARCH DESIGN AND METHODS: Diabetes, HbA1c, and FG were assessed at baseline, and frailty status was evaluated with a 36-item frailty index every 2 years during a 10-year follow-up among participants from the English Longitudinal Study of Ageing (ELSA). Mixed-effects models with age as time scale were used to assess whether age trajectories of frailty differed as a function of diabetes, HbA1c, and FG. RESULTS: Among 5,377 participants (median age [interquartile range] 70 [65, 77] years, 45% men), 35% were frail at baseline. In a model adjusted for sex, participants with baseline diabetes had an increased frailty index over aging compared with those without diabetes. Similar findings were observed with higher levels of HbA1c, while FG was not associated with frailty. In a model additionally adjusted for income, social class, smoking, alcohol, and hemoglobin, only diabetes was associated with an increased frailty index. Among nonfrail participants at baseline, both diabetes and HbA1c level were associated with a higher increased frailty index over time. CONCLUSIONS:People with diabetes or higher HbA1c levels at baseline had a higher frailty level throughout later life. Nonfrail participants with diabetes or higher HbA1c also experienced more rapid deterioration of frailty level with aging. This observation could reflect a role of diabetes complications in frailty trajectories or earlier shared determinants that contribute to diabetes and frailty risk in later life.
Authors: Cynthia M F Monaco; Mark A Tarnopolsky; Athan G Dial; Joshua P Nederveen; Irena A Rebalka; Maria Nguyen; Lauren V Turner; Christopher G R Perry; Vladimir Ljubicic; Thomas J Hawke Journal: Diabetologia Date: 2021-08-14 Impact factor: 10.122
Authors: Lucinéia Orsolin Pfeifer; Angélica Trevisan De Nardi; Larissa Xavier Neves da Silva; Cíntia Ehlers Botton; Daniela Meirelles do Nascimento; Juliana Lopes Teodoro; Beatriz D Schaan; Daniel Umpierre Journal: Sports Med Open Date: 2022-03-04